Gallbladder carcinoma

Summary

Gallbladder carcinoma (MONDO:0003220) is a cancer (an umbrella term covering 5 Mondo subtypes) and 189 clinical trials. Top therapeutic interventions include cisplatin, gemcitabine, and lapatinib. A subtype of gallbladder cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 189

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gallbladder carcinoma
Mondo ID	MONDO:0003220
EFO	EFO:1001956
DOID	DOID:4948
NCIT	C3844
SNOMED CT	372140005
UMLS	C0235782
MedGen	116001
GARD	0023412
Anatomy (UBERON)	UBERON:0002110
Is cancer (heuristic)	yes

Also known as: cancer of gallbladder · cancer of the gallbladder · carcinoma of gall bladder · carcinoma of gallbladder · carcinoma of the gallbladder · gall bladder carcinoma · Gall bladder carcinoma (adeno) · Gall bladder carcinoma (adenocarcinoma) · gallbladder cancer · gallbladder carcinoma

Data availability: 93 cell lines · 10 intOGen driver records.

Disease family

This is a subtype of gallbladder cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gallbladder cancer › gallbladder carcinoma

Related subtypes (4): gallbladder sarcoma, neurofibroma of gallbladder, gallbladder lymphoma, gallbladder melanoma

Subtypes (5): gall bladder carcinoma in situ, gallbladder adenocarcinoma, gallbladder small cell neuroendocrine carcinoma, gallbladder squamous cell carcinoma, undifferentiated gallbladder carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Capecitabine	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Gemcitabine	Phase 3 (in late-stage trials)
Oxaliplatin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Afatinib, Atezolizumab, Carboplatin, Cobimetinib, Durvalumab, Fluorouracil, Rivoceranib, Selumetinib, Tegafur.

Clinical trials & evidence

Clinical trials

Clinical trials: 189.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	75
Not specified	60
PHASE1	30
PHASE3	13
PHASE2/PHASE3	5
PHASE1/PHASE2	5
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00280709	PHASE4	COMPLETED	Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction
NCT02170090	PHASE3	ACTIVE_NOT_RECRUITING	Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT04559139	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT05833815	PHASE2/PHASE3	RECRUITING	Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
NCT06712420	PHASE3	RECRUITING	Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
NCT00253617	PHASE3	WITHDRAWN	Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
NCT00262769	PHASE3	COMPLETED	Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
NCT00304135	PHASE2/PHASE3	COMPLETED	Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
NCT00363584	PHASE3	COMPLETED	Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
NCT00387348	PHASE3	TERMINATED	Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
NCT00391183	PHASE2/PHASE3	COMPLETED	Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.
NCT00513539	PHASE3	COMPLETED	Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery
NCT00658593	PHASE3	TERMINATED	Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
NCT01313377	PHASE3	COMPLETED	Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
NCT01926236	PHASE3	COMPLETED	Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
NCT03579758	PHASE3	WITHDRAWN	Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
NCT03768414	PHASE3	COMPLETED	Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT03779035	PHASE3	UNKNOWN	Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
NCT04066491	PHASE2/PHASE3	TERMINATED	Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
NCT02151084	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT04068194	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
NCT04183712	PHASE2	RECRUITING	Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
NCT04308174	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
NCT04430738	PHASE2	ACTIVE_NOT_RECRUITING	Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04941287	PHASE2	ACTIVE_NOT_RECRUITING	Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
NCT05564403	PHASE2	ACTIVE_NOT_RECRUITING	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05757336	PHASE2	RECRUITING	Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
NCT06717464	PHASE2	ACTIVE_NOT_RECRUITING	Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
NCT06963060	PHASE2	ENROLLING_BY_INVITATION	Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
NCT07146646	PHASE2	RECRUITING	Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
NCT00003276	PHASE2	COMPLETED	Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer
NCT00003296	PHASE2	UNKNOWN	Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
NCT00003557	PHASE2	COMPLETED	Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
NCT00003923	PHASE2	COMPLETED	Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
NCT00005938	PHASE2	COMPLETED	DX-8951f in Treating Patients With Biliary Cancer
NCT00005997	PHASE2	TERMINATED	Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
NCT00009893	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
NCT00012246	PHASE2	TERMINATED	Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
NCT00023946	PHASE2	TERMINATED	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	24
GEMCITABINE	4	6
LAPATINIB	4	6
PORFIMER SODIUM	4	3
ERLOTINIB	4	2
OXALIPLATIN	4	2
SELUMETINIB	4	2
SORAFENIB	4	2
CAPECITABINE	4	1
CITALOPRAM	4	1
ESCITALOPRAM	4	1
IXABEPILONE	4	1
LEVOLEUCOVORIN	4	1
PALONOSETRON HYDROCHLORIDE	4	1
SARGRAMOSTIM	4	1
VANDETANIB	4	1
BINTRAFUSP ALFA	3	2
EXATECAN	3	2
BECATECARIN	3	1
CEDIRANIB MALEATE	3	1
INCOMPLETE FREUND’S ADJUVANT	3	1
TRIAPINE	3	1
DAVANAT	2	1
DOLASTATIN-10	2	1
CHEMBL541887	0	1